What conditions need to be met to participate in the clinical use of lorlatinib in Hong Kong?

In Hong Kong, lorlatinib (Lorlatinib) is mainly used to treat patients with ALK positive non-small cell lung cancer (NSCLC) patients, especially those who have developed drug resistance or disease progression after previous treatment with crizotinib and other second-generation ALK inhibitors (such as alectinib, brigatinib, etc.). If patients wish to participate in clinical drug projects, they must first have a clear medical diagnosis certificate. They usually need to detect a positive ALK fusion mutation through tissue biopsy or liquid biopsy, and have their treatment history and drug resistance evaluated by an oncologist before they can apply.

In addition to the requirements for genetic mutations at the molecular level, patients also need to meet certain physical condition assessment standards. For example, the ECOG physical status score needs to be 0-2 points, indicating that the patient has good daily activities and can tolerate oral targeted drug treatment; at the same time, laboratory indicators such as liver and kidney function, electrolytes, and blood tests also need to be within a safe range to reduce the risk of serious adverse reactions after taking the drug. In addition, patients may be excluded from clinical use if they have uncontrolled brain metastases, severe heart disease, or other comorbidities.

The use of lorlatinib in Hong Kong is sometimes carried out through the "Compassionate Use" program or the "Patient Assistance Program" (PAP), but may also be included in research-based real-world use projects. In this case, the patient also needs to sign an informed consent form to clearly understand the possible effects and risks of the drug. At the same time, it is necessary to regularly cooperate with doctors to conduct imaging follow-up and blood monitoring so that the project party can evaluate the efficacy and safety.

In short, patients who want to participate in the clinical use of lorlatinib in Hong Kong must have ALKpositiveNSCLC diagnosis results, meet treatment resistance conditions and relevant physical index requirements, and be willing to cooperate with the project process and follow-up plan. It is recommended that patients undergo evaluation through regular Hong Kong hospitals or cross-border oncology clinics and be guided by professional doctors to ensure the safety and rationality of medication.

Reference materials:https://www.drugs.com/